QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NYSE:MRK

Merck & Co., Inc. (MRK) Stock Forecast, Price & News

$108.60
-1.41 (-1.28%)
(As of 06/7/2023 ET)
Compare
Today's Range
$106.87
▼
$109.67
50-Day Range
$104.92
▼
$118.38
52-Week Range
$83.05
▼
$119.65
Volume
12.42 million shs
Average Volume
7.85 million shs
Market Capitalization
$275.57 billion
P/E Ratio
21.21
Dividend Yield
2.69%
Price Target
$120.75
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
11.2% Upside
$120.75 Price Target
Short Interest
Healthy
0.77% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.31
Upright™ Environmental Score
News Sentiment
0.07mentions of Merck & Co., Inc. in the last 14 days
Based on 23 Articles This Week
Insider Trading
Selling Shares
$56.48 M Sold Last Quarter
Proj. Earnings Growth
21.73%
From $6.95 to $8.46 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.17 out of 5 stars

Medical Sector

8th out of 982 stocks

Pharmaceutical Preparations Industry

5th out of 468 stocks

See Top Rated MarketRank™ Stocks Here

MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. is a US-based multinational pharmaceutical and healthcare company. It was officially founded in 1891 as the US arm of Merck Group, headquartered in Germany. Merck Group was founded in 1668 when Friedrick Jacob Merck purchased a pharmacy in Darmstadt, Germany. The company transformed from a pharmacy into a drug manufacturer in 1827 with the commercialization of morphine and the perfection of the manufacturing process. The company will later gain recognition for isolating and commercializing the manufacture of cocaine as well.

Merck Group sent Theodore Weicker to New York as its representative in 1889 and he quickly began to set up operations. The original investment of $200,000 resulted in a facility in lower Manhattan and the addition of Merck family member George Merck to the project. They began operations in 1891 and were in business as the US branch of Merck Group until 1917 and the onset of World War I.

World War I brought about the Trading With The Enemy Act of 1917 and the nationalization of Merck Group’s US operations. Those operations were repurchased at a government auction only 2 years later with the help of Goldman Sachs and Lehman Brothers, but the split was done. The company retained rights to the Merck name in the US but remained independent. One of many noteworthy achievements in the post-War period is the discovery of streptomycin, which was revolutionary in treating tuberculosis.

In 1953 the company merged with Sharp& Dohme to form the then 2nd largest US drug manufacturer. The merger brought smallpox vaccines to the portfolio and opened a new avenue of research for the business. Since then, advancements in vaccine technology include treatments for mumps and chickenpox. Other notable advancements include the discovery of statins as a cholesterol inhibitor and work in veterinary medicine.

Today, Merck & Co operates through 2 segments and under 2 different names with a headquarters in Kenilworth, NJ.  The company operates as Merck & Co in the US and as Merck Sharp & Dohme outside the US and Canada. The 2 segments are Pharmaceutical and Animal Health. Revenue topped $49 billion in 2022 and employed more than 68,000 people. The company has 8 research facilities near major university systems, including 7 in the US and 1 in the UK. As of 2022, the company had 82 pipeline products in Phase 2 trials, 30 in Phase 3 trials and 3 under review.

The Pharmaceutical segment researches discover and commercializes human health products in several areas of medicine. These include but are not limited to oncology, acute care, immunology, neuroscience, virology, cardiovascular, and diabetes. This segment has 6 blockbuster drugs as of late 2022, with each generating more than $1 billion in revenue. The leading treatments are Keytruda for treating cancer-related immune conditions, Gardisil which is a vaccine for HPV and Januvia for treating Type-II diabetes. The Animal Health segment discovers, develops, manufactures, and markets veterinary healthcare products and services. Both segments sell to healthcare facilities and distributors.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

May 30, 2023 | marketbeat.com
Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application (MRK)
Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug Admin
May 18, 2023 | marketbeat.com
Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (MRK)
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
June 7, 2023 | Behind the Markets (Ad)
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
June 7, 2023 | msn.com
Merck (MRK) Sues US Government to Halt Drug Price Negotiations
June 7, 2023 | seekingalpha.com
Merck's Strength Is Nothing To Be Afraid Of
June 7, 2023 | markets.businessinsider.com
Merck & Company (MRK) Gets a Buy from SVB Securities
June 7, 2023 | finance.yahoo.com
Drug Maker Merck Sues US Gov. Over Inflation Reduction Act
June 6, 2023 | seekingalpha.com
asco-investor-event-slides-final-for-website
June 7, 2023 | Behind the Markets (Ad)
Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"
Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>
June 6, 2023 | finance.yahoo.com
Merck Sues To Stop Medicare Drug Negotiation
June 6, 2023 | finance.yahoo.com
Merck Challenges U.S. Government’s New Powers to Negotiate Drug Prices
June 6, 2023 | finance.yahoo.com
UPDATE 1-Merck sues US government to halt Medicare drug price negotiation
June 6, 2023 | seekingalpha.com
Merck: Keytruda's Continued Oncology Success And Other Prospects
June 6, 2023 | markets.businessinsider.com
Barclays Keeps Their Buy Rating on Merck & Company (MRK)
June 6, 2023 | seekingalpha.com
Merck & Co., Inc. (MRK) Special Event (Oncology Investor Event at ASCO 2023) Transcript
June 6, 2023 | seekingalpha.com
Merck & Co., Inc. (MRK) Presents at Special Event (Oncology Investor Event at ASCO 2023) Transcript
June 5, 2023 | finance.yahoo.com
Moderna and Merck Report Significant Success in Investigational Skin Cancer Therapy, Cuts Risk Of Distant Metastasis Or Death By 65%
June 5, 2023 | markets.businessinsider.com
Merck & Company (MRK) Gets a Hold from BMO Capital
June 5, 2023 | markets.businessinsider.com
Merck & Company (MRK) Receives a Buy from Bank of America Securities
June 3, 2023 | finance.yahoo.com
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC
June 3, 2023 | finance.yahoo.com
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma
June 2, 2023 | reuters.com
BioNTech says drug from OncoC4 partnership shows promise in mid-stage trial
June 2, 2023 | americanbankingnews.com
Brokerages Set Merck & Co., Inc. (NYSE:MRK) PT at $120.75
June 1, 2023 | forbes.com
Is Merck Stock A Better Pick Over ABBV?
June 1, 2023 | finance.yahoo.com
FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
May 31, 2023 | thestreet.com
Merck & Co Inc (MRK): Today's Featured Health Care Winner
May 31, 2023 | finance.yahoo.com
New Pfizer RSV Vaccine Rolls Out Into Headwinds of Hesitancy
See More Headlines

MRK Price History

MRK Company Calendar

Ex-Dividend for 4/10 Dividend
3/14/2023
Dividend Payable
4/10/2023
Last Earnings
4/27/2023
Today
6/07/2023
Ex-Dividend for 7/10 Dividend
6/14/2023
Dividend Payable
7/10/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:MRK
CUSIP
58933Y10
CIK
310158
Web
www.merck.com
Phone
(908) 740-4000
Fax
908-735-1253
Employees
69,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$120.75
High Stock Price Forecast
$135.00
Low Stock Price Forecast
$98.00
Forecasted Upside/Downside
+11.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
23 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$5.12
Trailing P/E Ratio
21.21
Forward P/E Ratio
15.63
P/E Growth
1.97
Net Income
$14.52 billion
Net Margins
22.52%
Pretax Margin
26.32%
Return on Equity
37.92%
Return on Assets
15.90%

Debt

Debt-to-Equity Ratio
0.60
Current Ratio
1.44
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$59.28 billion
Price / Sales
4.65
Cash Flow
$8.67 per share
Price / Cash Flow
12.52
Book Value
$18.17 per share
Price / Book
5.98

Miscellaneous

Outstanding Shares
2,537,440,000
Free Float
2,532,361,000
Market Cap
$275.57 billion
Optionable
Optionable
Beta
0.35

Social Links


Key Executives

  • Robert M. DavisRobert M. Davis
    Chairman, President & Chief Executive Officer
  • Caroline A. LitchfieldCaroline A. Litchfield
    Chief Financial Officer & Executive Vice President
  • Dave Williams
    Chief Information & Digital Officer
  • Lisa LeCointe-Cephas
    Senior VP, Chief Ethics & Compliance Officer
  • Sanat ChattopadhyaySanat Chattopadhyay
    EVP & President-Merck Manufacturing Division

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 7 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MRK shares.
View MRK analyst ratings or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2023?

23 analysts have issued 1-year price targets for Merck & Co., Inc.'s shares. Their MRK share price forecasts range from $98.00 to $135.00. On average, they predict the company's stock price to reach $120.75 in the next year. This suggests a possible upside of 11.2% from the stock's current price.
View analysts price targets for MRK or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2023?

Merck & Co., Inc.'s stock was trading at $110.95 at the beginning of 2023. Since then, MRK stock has decreased by 2.1% and is now trading at $108.60.
View the best growth stocks for 2023 here.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our MRK earnings forecast.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) posted its quarterly earnings results on Thursday, April, 27th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.34 by $0.06. The business earned $14.49 billion during the quarter, compared to analyst estimates of $13.81 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 37.92% and a net margin of 22.52%. Merck & Co., Inc.'s quarterly revenue was down 8.9% compared to the same quarter last year. During the same period last year, the firm posted $2.14 EPS.
Read the conference call transcript.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 23rd. Stockholders of record on Thursday, June 15th will be given a dividend of $0.73 per share on Monday, July 10th. This represents a $2.92 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Wednesday, June 14th.
Read our dividend analysis for MRK.

What ETFs hold Merck & Co., Inc.'s stock?

ETFs with the largest weight of Merck & Co., Inc. (NYSE:MRK) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Invesco S&P 500 Momentum ETF (SPMO), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Health Care Select Sector SPDR Fund (XLV), Invesco Dynamic Pharmaceuticals ETF (PJP), VanEck Pharmaceutical ETF (PPH), iShares U.S. Healthcare ETF (IYH) and Absolute Select Value ETF (ABEQ).

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.92 per share and currently has a dividend yield of 2.58%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 57.03%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 34.52% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share (EPS) guidance of $6.88-$7.00 for the period, compared to the consensus estimate of $6.91. The company issued revenue guidance of $57.70 billion-$58.90 billion, compared to the consensus revenue estimate of $58.28 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.24%), State Street Corp (4.59%), Wellington Management Group LLP (2.70%), Geode Capital Management LLC (2.02%), FMR LLC (1.41%) and Charles Schwab Investment Management Inc. (1.21%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Johannes Jacobus Oosthuizen, Joseph Romanelli, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Steven Mizell.
View institutional ownership trends.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $108.60.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $275.57 billion and generates $59.28 billion in revenue each year. The company earns $14.52 billion in net income (profit) each year or $5.12 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 69,000 workers across the globe.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -